TABLE 1.

Animals and experimental groups used for this study

Treatment group	Characteristics of experimental animalsb			Characteristics of attenuated virus vaccinationc			Challenge virus	Antibody treatment
	Animal no.	Sex	MHC class I status (Mamu-A*01)	Virus	Inoculation route	Mos of infection
Vaccinated with attenuated virus, treated with control MAb	N374	F	Neg	SIVmac239Δ3	i.v.	63	None	Control MAb
	N029	F	Neg	SIVmac239Δ3	i.v.	63	None	Control MAb
Vaccinated with attenuated virus, treated with anti-CD8 MAb	JW3	M	Neg	SIVmac239Δ3	CNS	57	None	Anti-CD8
	BB4	M	Pos	SIVmac239Δ3	CNS	57	None	Anti-CD8
Vaccinated with attenuated virus, treated with control MAb challenged with pathogenic virus	17141	M	Neg	SIVmac239Δ3	i.v.	66	SIVmac251	Control MAb
	17152	M	Neg	SIVmac239Δ3	i.v	66	SIVmac251	Control MAb
	KY3	F	Neg	SIVmac239Δ3	i.v. and p.o.	55	SIVmac251	Control MAb
	SR3	F	Pos	SIVmac239Δ3	i.v. and p.o.	55	SIVmac251	Control MAb
	N437a	F	Neg	SIVmac239Δ3	i.v.	63	SIVmac251	Control MAb
	6543a	F	Neg	SIVmac239Δ3	i.v.	63	SIVmac251	Control MAb
Vaccinated with attenuated virus, treated with anti-CD8 MAb challenged with pathogenic virus	17175	M	Neg	SIVmac239Δ3	i.v.	66	SIVmac251	Anti-CD8
	17178	M	Pos	SIVmac239Δ3	i.v.	66	SIVmac251	Anti-CD8
	63-88	F	Neg	SIVmac239Δ3	i.v.	55	SIVmac251	Anti-CD8
	LY3	M	Pos	SIVmac239Δ3	CNS	57	SIVmac251	Anti-CD8
	QS3	M	Neg	SIVmac239Δ3	i.v. and p.o.	55	SIVmac251	Anti-CD8
	RN913a	F	Pos	SIVmac239Δ3	p.o.	62	SIVmac251	Anti-CD8
	96Ha	F		SIVmac239Δ3	i.v.	64	SIVmac251	Anti-CD8
Challenged with pathogenic virus only	17181	M	Neg	None	NA	NA	SIVmac251	None
	17174	M	Neg	None	NA	NA	SIVmac251	None
	RSZ-7	M	Neg	None	NA	NA	SIVmac251	None
	RUA-7	M	Neg	None	NA	NA	SIVmac251	None

^aThese animals received the first antibody administration 6 h prior to SIV challenge. All other antibody-treated and SIV-challenged animals received the first antibody administration 3 days prior to SIV challenge.

^bM, male; F, female; Neg, negative; Pos, positive.

^ci.v., intravenous; CNS, central nervous system; p.o., per os; NA, not applicable.